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ABSTRACT: Cells microencapsulated in biocompatible semi-permeable poly-
meric membranes are effective as cell delivery systems while protecting the host
against immune responses. In this study, cell encapsulation membranes were
prepared based on carrageenan and alginate, two natural cationic polymers.
Different formulations/conditions were explored to optimize the microcapsules
which were characterized with respect to their morphology, mechanical stability,
and cytotoxicity. Spherical-shaped microcapsules were obtained from all the
polymeric systems. The iota-carrageenan/sodium alginate microcapsules exhib-
ited the best stability and permeability, and therefore, these were selected for
the cell encapsulation. These capsules provided an environment that supported
cell proliferation and have the potential for tissue engineering as well as other
cell-based therapy applications.
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INTRODUCTION
An effective method of immunoprotecting cells and proteins forimplantation into unmatched recipients, as well as delivery via
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injection into a target defect, is encapsulation [1]. The polymers and
procedures used for encapsulation are especially important for tissue
engineering applications [2]. Several polymers have been studied for
microcapsule formation, such as agarose, alginate, polyacrylates,
poly(vinyl alcohol), chitosan, and poly(L-lysine) [3,4], with the objective
of enhancing and optimizing the cell immobilization by maintaining the
general cell functions and survival rates [5,6]. It is important to obtain
biocompatible and semi-permeable polymeric membranes that allow
molecular transport and cell survival within the capsules [7].
This study describes the combination of two natural polymers, iota-
carrageenan and sodium alginate (both polyanions), for encapsulating
living cells. Carrageenans form helical structures with the ability to
form gels at room temperature [8]. Their main chain consists of
alternating copolymers of 1,4-b and 1,3-a-D-galactopyranose as well as
3,6-anhydro-D-galactopyranose. The main structural differences in the
three different types of carrageenans (iota, kappa, and lambda) is
in the degree of sulfate substitution [8,9]. In the case of iota- and
kappa-carrageenan, the chemical structure of iota-carrageenan differs
from that of kappa-carrageenan by the presence of an additional sulfate
group in the 3,6-anhydrogalactosyl residue, which confers a more
hydrophilic character to the molecule [10,11]. Previous investigations
have reported the development of capsules using carrageenan
and oligochitosan polymer [8] for the encapsulation of microbial
cells [12–14].
Alginate is composed of mannuronic (M) and guluronic (G) acids and
is a commonly employed polysaccharide for cell encapsulation [15].
However, alginate capsules have poor mechanical stability and usually
require further treatment with citrate to liquefy the core of the capsules
to enable cell survival [15–18]. Chitosan is a linear polysaccharide
produced by the deacetylation of chitin [19] used for a variety of
powders, gels, porous structures, fibers, membranes, and films for
biomedical applications [20–24].
The aim of this work was to combine the advantageous features of
alginate with those of carrageenan and chitosan to form capsule
membranes. Chitosan with its positive charges were interacted with
the anionic alginate and carrageenan, to create a membrane at the
capsule’s surface, which could improve the mechanical stability of
the structures [25]. Capsules, based on different formulations and
conditions, were studied with respect to their morphology,
mechanical stability, cytotoxicity, and ability to maintain the viability
of encapsulated cells.
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MATERIALS AND METHODS
Materials
Iota-carrageenan (22045), kappa-carrageenan (22048), sodium algi-
nate (71238), b-glycerophosphate disodium salt (b-GP/G9891), phosphate
buffer saline (PBS-P4417), sodium citrate (S1804), and DAPI (406-
diamidino-2-phenylindole/D9564) were purchased from Sigma
(Portugal). Low molecular weight (Mw) chitosan powder was obtained
from Aldrich/448869 (Portugal). Calcein-AM (acetoxymethyl ester of
calcein) was purchased from Invitrogen/C3099 (Portugal).
Adjustment of the pH of the Chitosan Solutions with b-GP
A solution containing 0.0266 g/mL of b-GP was slowly added to a
chitosan solution (0.30% in 0.017M HCl) until physiological pH 7 was
obtained. At this point, precipitation occurs. A curve of the variation of
the pH in chitosan solution as a function of b-GP concentration was
developed to determine the amount of b-GP to be added to reach the
desired pH.
Microcapsules Based on Iota- and Kappa-Carrageenan
Capsules were obtained using chitosan solutions at two different pHs,
5.0 and 6.0, adjusted with b-GP. The microcapsules were obtained by
adding 1mL of an 1.5% aqueous solution of iota (or kappa)-carrageenan
dropwise througha0.3mmneedle (BD-MicrofineU-100 insulin,Portugal,
using an AL-1000, Aladdin Programmable Syringe Pump) into 20mL of
an 0.15% chitosan in a solution at 0.0085M HCl. The capsules were
allowed to harden for 45min at 378C in a water bath, washed with 0.9%
NaCl and immersed in a 0.05% iota-carrageenan solution for 5min in
order to link the remaining residues of chitosan. The capsules were then
rinsed twice with PBS and stored at 48C in the same buffer.
Sodium Alginate/Iota-carrageenan Microcapsules
Aqueous alginate/iota-carrageenan mixtures composed of a 1.5%
aqueous solution of each polymer, at two different ratios, 50/50 and
30/70 (v/v), were prepared as follows. A mixture of 1mL was extruded
using a 0.3mm syringe into 20mL solution of 0.05M CaCl2 and
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0.2M NaCl in distilled water. The microcapsules were allowed to harden
for 30min at 378C. The capsules were then immersed in 20mL of chitosan
solutions (pH 5.0 and 6.0) prepared as described above for 20min at 378C.
The capsules were rinsed with PBS for 1min and immersed in a 0.05%
iota-carrageenan for 5min. Microcapsules with liquedied core were also
prepared using sodium citrate. The obtained iota-carrageenanþ alginate
microcapsules obtained above were immersed in a 0.055M solution of
sodium citrate for 1min [5,26]. Immersion times41.5min disintegrated
the liquefied capsules; therefore, 1min was chosen for comparison with
solid capsules. The obtained capsules (solid and liquefied) were rinsed
twice with PBS buffer and stored at 48C in the buffer for characterization.
The capsules were immersed in Dulbecco’s Modified Eagle’s Medium
(DMEM) to assess the stability of the microcapsules in culture medium
and to observe the capsule permeability.
Morphological Characterization of Microcapsules
The size and shape of the microcapsules were examined by
stereomicroscopy (Zeiss–Stemi 2000-C KL 1500 LCD, 459315) and
with an inverted light microscope (Zeiss, Axiovert 40 CFL, 459306). The
capsules were stained in 0.1% (w/v) eosin dye (eosin Y solution, alcoholic
with phloxine B 0.1% (w/v)/HT110316, Sigma-Aldrich, Portugal) to
observe the membranes.
Evaluation of Mechanical Stability
Both the solid and partially liquefied microcapsules produced were
submitted to a short-term stability evaluation assay and 50 capsules of
each type were placed in 24 well plates (10 per well) with 800 mL of PBS
solution in each well. The culture plate was then agitated at 200 rpm
and 258C for different periods of time, namely 1, 3, 6, 24, and 48h. The
percentage of ruptured capsules, as a function of time, was determined
by stereomicroscopy.
Assessment of in vitro Cytotoxicity of the Developed Capsules
To evaluate possible toxic effects of leachables from the microcapsules
and polyanions used, MTT testing was used. Latex rubber (Dermagip,
WRP) was used as a positive control and standard culture plates (Costar
96 well plate) were used as a negative control. Extracts of the capsules
and the positive control were obtained by immersion in culture medium
for 24 h at 378C and 60 rpm.
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Cell Culture
A mouse lung fibroblast cell line (L929), obtained from European
Collection of Cell Cultures (ECC, UK), was used for the cytotoxicity
assays. The cells were grown as monolayer in 75 cm2 culture flasks,
using DMEM-low glucose (DMEM-Sigma-Aldrich), supplemented with
10% fetal bovine serum (FBS), 1% antibiotic/antimycotic and sodium
bicarbonate at 378C in a 5% CO2 incubator. Cells were harvested before
reaching confluence from 75 cm2 culture flasks using trypsin–EDTA,
and a cell suspension was prepared to obtain a cell density of
6.6" 104 cells/mL. Cell suspension (200 mL/well) was cultured in a 96
well culture plate in DMEM. After the cells were attached to the culture
plate, the culture medium was replaced by 150 mL of extracted capsules
prepared in complete culture medium and incubated for 24, 48, and 72h
at 378C.
Preparation of the Extracts
The extracts were obtained by immersing 100 microcapsules (of each
type) in a sterile tube containing 5mL of DMEM and placed in a water
bath at 378C and 60 rpm for 24 h and the extract filtered using a 0.45mm
syringe filter. As a positive control, 60 squares of 1 cm2 of latex rubber
were immersed in DMEM culture medium following the same procedure
described for the tested materials.
MTT Assay
The MTT solution (50 mL of 1mg MTT/mL DMEM without phenol
red) was added to the cell monolayers, previously exposed to extracts
obtained from the capsules and incubated at 378C in a 5% CO2 incubator
for 4 h. The MTT solution was removed and replaced by 10 mL of
isopropanol to lyse the cells [27]. The solution became purple and the
optical density (OD) was measured in a microplate reader (BIO-TEK –
Synergy HT) at 570 nm, with a background correction of the OD at
650 nm. The results were expressed as percentage of cell viability
calculated using the following equation:
Cell viability ð%Þ ¼ ðODsample=ODcontrolÞ " 100 ð1Þ
where ODsample is the OD obtained in the cells exposed to each extract/
capsule and ODcontrol the OD obtained in the cells incubated with the
culture medium only (negative control) [28].
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Cell Encapsulation
Immobilization of the cells was performed using a L929 fibroblasts cell
line in sodium alginate/iota-carrageenan solid and liquefied capsules.
Microcapsules and cell encapsulation procedures were carried out at
room temperature under sterile conditions, using a laminar flow
cabinet. All solutions were prepared in distilled water and filtered
using a 0.2 mm membrane filter (Schleicher & Schuell Microscience,
Germany). The sodium alginate, iota-carrageenan and chitosan solu-
tions were autoclaved prior to use. The fibroblast cells were initially
harvested from monolayer using trypsin–EDTA (Invitrogen, Portugal).
A suspension containing 5" 103 cells per mL of the polymeric solution
were mixed with the sodium alginate/iota-carrageenan (30/70) solution.
The cell-polymeric suspension was extruded into a calcium chloride–
sodium chloride (CaCl2–NaCl) solution, as described above using a
syringe pump. The resulting microcapsules/cells were maintained in
CaCl2–NaCl for 30min at 378C in a 5% CO2 incubator. The capsules
containing the cells were then immersed in 20mL of chitosan solution
(adjusted to pH 5.0 with b-GP) for 10min and at 378C in a 5% CO2
incubator. The capsules were rinsed with PBS for 1min and immersed
in 0.05% iota-carrageenan for 5min. To obtain the liquefied capsules,
the microcapsules with cells were treated with 0.055M of sodium citrate
for 1min. Finally, microcapsules with cells were washed twice with PBS,
transferred to a 6 well culture plate and immersed in culture medium.
The encapsulated cells were cultured in a 5% CO2 incubator for different
periods of time, 1, 2, 3, and 7 days. The culture medium was changed
every 2 days.
Morphological Characterization in Encapsulated Cells
The morphology of the microcapsules containing the cells as well as
the morphology of the cells, were analyzed using inverted light
microscopy and a stereomicroscopy, respectively. The viability of the
encapsulated cells were assessed using the methylene blue staining.
MTS Assay
Cellular viability of entrapped fibroblast cells was determined using
the MTS testing [29,30]. The microcapsules (30/70) containing cells
(three capsules per well) were immersed in a culture medium containing
MTS, in a 5:1 ratio, and incubated at 378C. After 3 h of incubation,
100 mL of the solution obtained from each well (containing the
encapsulated cells) were transferred to a 96-well plate. The absorbance
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was read with a microplate reader (BIO-TEK – Synergy HT) at 490 nm.
An alginate/iota-carrageenan mixture (30/70) of fibroblasts cells was
used as the control.
Staining of Calcein-AM and DAPI Fluorescents
Two fluorescent dyes were used to assess the cellular viability in
encapsulated cells. Calcein-AM, a green dye, was used to identify the
viable cells and DAPI, a blue dye, was used to identify cell nucleus in live
and fixed cells. In this assay, the capsules were placed into an Eppendorf
tube containing 1mL of DMEM and 2 mL of Calcein-AM and incubated
for 20min at 378C in 5% CO2. The capsules were then rinsed in DMEM
culture medium and PBS solution. The PBS was replaced by 500 mL of
glutaraldehyde (2.5%) for 10min at room temperature to fix the cells.
The excess glutaraldehyde was removed and the capsules were rinsed
twice in PBS. A new PBS solution (1mL) and 2 mL of DAPI were added
to the capsules and incubated for 20min at 378C in 5% CO2. The
capsules were rinsed twice in PBS and observed under a fluorescence
microscope (Zeiss 434301) using Alexa Flour 488 and DAPI 49. All the
procedures were performed in the dark.
Statistical Analysis
The results obtained in the mechanical stability tests and in the MTT
(in vitro cytotoxicity of capsules’ leachables) and MTS tests (as cellular
viability of encapsulated cells) are presented as means& standard
deviation. The statistical analysis of the results was performed using
the Student’s t-test, with a significance level of 95% ( p50.05).
RESULTS AND DISCUSSION
Microcapsules were formed as iota- or kappa-carrageenan complexes.
Both carrageenans have polyelectrolytic character and form a
thermoreversible gel, which is induced by selected monovalent and/
or divalent metal cations [8,11]. Based on stereomicroscope and
inverted light microscope observations, the kappa- and iota-
carrageenans formed spherical-shaped microcapsules with 2.0–2.2mm
diameters (Figure 1).
In this study, chitosan solutions, with different pHs were used to form
different types of capsules by polyelectrolyte complex and ionotropic
gelation method, since changes in the pH alters the protonation degree
and bonding interactions in chitosan [31].
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Previous studies have demonstrated that chitosan can be neutralized
to physiological pH (7.2) using b-GP, without promoting the precipita-
tion [31,32]. The capsules formed at pH 5.0, exhibited a smoother
surface than the capsules formed at pH 6.0. At pH 5.0, the capsules have
higher chitosan protonation that can induce a more homogeneous
complex. These results are in accordance with alginate/oligochitosan
and carrageenan/oligochitosan systems developed in other studies,
where a more compact polyelectrolyte complex with higher crosslinking
density was formed [8,17,33].
The thickness and strength of the capsule wall were controlled by
varying the Mw of the constituent polymers. The lower Mw forms
diffuse through the capsule membrane more rapidly, thus produce
thicker walls before being hampered by the diffusion distance. The lower
Mw chitosan capsule walls are both thicker and less elastic than those
made with higher Mw forms [34]. As a result, the diluted chitosan
solution (0.15%) used in the capsules developed produced a membrane
with less elasticity but with fewer incidences of physical defects.
Moreover, the low Mw chitosan increases its capacity to penetrate and
interact with the core polymer [2].
In general, kappa-carrageenan generated thicker gels in the core as
compared to iota-carrageenan (Figure 1), which might compromise the
exchange of gases and nutrients, harming the viability of the encapsu-
lated cells. Therefore, iota-carrageenan was selected for further studies,
concerning the development of microcapsules based on the combination
of this polymer with alginate. Previous studies [17] have demonstrated
that iota-carrageenan and alginate are similar because both polymers
Figure 1. Optical microscopy images taken at pH 5.0 of microcapsules: (A1–A3) kappa-
carrageenan and (B1–B3) iota-carrageenan (1.5", 4", 5").
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have one anionic group per glucosic unit, producing a more compact and
resistant capsule in comparison with kappa-carrageenan which has a
lower degree of substitution (one anionic group per two glucosic unit).
The capsules alginate/iota-carrageenanwere produced by extruding from
amixture of the two polyanions into a gelling agent (CaCl2) and antigelling
agent (NaCl) [35]. According to optical microscope observations, the
capsules performed exhibited spherical shape, thin, and smooth surface and
revealed good stability in PBS and in culture medium (Figure 1). The
diameter of the solid capsules (non-liquefied) was '2.0mm, while the
average diameters of the liquefied capsules were 2.3mm. The increase in
diameter in liquefied capsules is due to the enhanced swelling of the
capsules [18]. The citrate, a sequestering agent, generates a strong bond
between calcium ions and non-gelling sodium or potassium ions. The
decrease of the Ca2þ bound between the alginate chains increases the
swelling pressure inside the capsule,modifying the original diameter [1,16].
The capsules obtained with different iota-carrageenan and alginate
ratios and different pHs showed similar size, shape and stability in PBS
and culture medium (Figure 2). However, the capsules obtained at pH
5.0 exhibited a smoother membrane and better handling properties in
comparison with capsules obtained at pH 6.0. In previous studies, the
pH of a solution was used to modulate the polyelectrolyte membranes.
For instance, the cationic polymer chitosan is soluble at low pH, but its
solubility decreases as alkaline pH is approached. Moreover, the
micropores of chitosan membrane capsule assume minimum dimensions
at low pH, but at about pH 6.0 and higher, repulsive forces produce the
pores to open up and the membrane permeation to rise.
Figure 2. Optical microscopic images of solid capsules with different polymer ratios and
at different pH: (A1–A2) microcapsules from sodium alginate/iota-carrageenan (30/70) at
pH 5; (B1–B2) microcapsules were obtained at pH 6; (C1–C2) microcapsules from (50/50)
at pH 5; and (D1–D2) microcapsules obtained at pH 6. The microcapsules (A, B, and D)
were dyed with eosin for observation (1", 1.5", 4").
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Previous studies showed that NaCl is one of the factors that determines
membrane permeability as well as surface topology [35]. The sodium ions
control the initial stages of complex formation. The negative charges of
the reacting polymers suppress the reaction of calcium ions with the
polyanion matrix. Therefore, by increasing the ratio of Naþ to Ca2þ for a
given polyanion mixture, it is possible to obtain a wrinkle-free surface [2].
The mechanical stability of microcapsules is a major concern in the
design of cell immobilization for therapeutic devices where good mechan-
ical stability is needed to prolong in vivo function [36]. The short-term
stability had similar numbers of ruptured capsules for all the systems
(Figure 3). The capsules produced using a mixture 50/50 sodium alginate/
iota-carrageenan of the polymers exhibited lower stability in the mechan-
ical study (&10%more of ruptured capsules) compared to capsules formed
using 30/70 SA-IC polymers. The increase in the iota-carrageenan content
of this formulation produced higher amounts of ionic sulfate groups that
repel each other and contribute for the molecules being highly extended.
The gradual substitution of alginate (a rigid polymer) with carrageenan (a
flexible polymer) provided the flexibility required to adapt to the varying
stress of tidal and wave motion caused by the agitation [37,38].
In the first 6h, liquefied and solid (non-liquefied) 50/50 SA-IC capsules,
presented similar behavior (Figure 4). However, the 30/70 SA-IC composi-
tion had greater mechanical stability for that time period. This suggests
that the decreasing stability is caused by the swelling effect related to the
treatment with sodium citrate, which affects the capsules with higher
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Figure 3. Percentage of ruptured microcapsules, corresponding to different sodium
alginate/iota-carrageenan ratios as a function of time.
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concentration of alginate. After 24h, rupturing of both 30/70 and 50/50
non-liquefied capsules increased, which could be related to the mass
transfer of PBS through the capsule membrane. It is known that mass
transfer is greater in liquefied capsules and that equilibrium is reached
faster than in the non-liquefied. However, before reaching equilibrium, the
mass transfer in the non-liquefied capsule may occur predominantly from
the solution to the interior of the capsules, leading to their bursting.
Solid capsules (non-liquefied) were reported to be mechanically more
resistant than liquefied capsules, which was attributed to the swelling effect
induced by the citrate solution during production of the liquefied capsules
[16,18,39]. In our study, statistically significant differences were not found
in the stability of solid and liquefied alginate/iota-carrageenan capsules,
probably due to the structure and distribution of the mixed polymers used.
Accordingly, the 30/70 sodium alginate/iota-carrageenan (solid and lique-
fied) capsules were selected for the posterior cell encapsulation assays.
Figure 4. Optical microscopy images of the capsules at different time periods. (A) 30/70 solid
capsules; (B) 30/70 liquefied capsules; (C) 50/50 solid capsules; and (D) 50/50 liquefied capsules.
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The metabolic activity and viability of the fibroblast cultured with
leachables extracted from 30/70 and 50/50 sodium alginate/iota-carragee-
nan solid capsules were assessed usingMTT test for three different periods
of culture (24, 48, and 72h). Optical observations (before adding the MTT
solution) revealed a good cell growth and attachment. No changes in cell
morphology were detected in comparison with negative control (Figure 5),
demonstrating the non-cytotoxicity of these capsule formulations. The cell
viability of all the capsules was similar for all the culturing periods.
However, the cell viability, determined using MTT in cells exposed to
extracts of 50/50 sodium alginate/iota-carrageenan capsules, was lower
compared to the cells exposed to the extract obtained from the 30/70
sodium alginate/iota-carrageenan capsules (Figure 6). The capsules with
higher alginate could be producing leachable material that induce a
reaction with the cells exposed to their extracts.
Viability and Proliferation of Encapsulated Cells
Based on the mechanical stability evaluation, it was decided to use the
30/70 sodium alginate/iota-carrageenan solid and liquefied capsules
Figure 5. Morphology of fibroblasts exposed to: (A) 30/70 SA-IC capsules extracts;
(B) 50/50 SAIC capsules extracts; (C) latex extracts (positive control); and (D) culture
medium (negative control) incubated 72h at 378C.
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obtained using a chitosan solution at pH 5.0, for the cell encapsulation.
The optical microscopy images of the capsules in culture medium and
stained with methylene blue show living cells with blue colored nucleus
(Figure 7). Seven days post-encapsulation, the cells exhibited similar
shapes and distribution in solid and liquefied capsules and no cell
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Figure 6. MTT tests of metabolic activity of the L929 fibroblasts cultured with extracts
obtained from 30/70 and 50/50 SA-IC solid capsules for 24, 48, and 72h.
Figure 7. Optical images of encapsulated fibroblasts (within sodium alginate/iota-
carrageenan (30/70) solid capsules pH 5.0: (A1–A3) cells within 30/70 SA-IC solid capsules
in culture medium (5" and 10", respectively); (B1) cells within 30/70 SA-IC solid capsules
in culture medium (20"); (B2–B3) cells within solid capsules stained with blue methylene
(20" and 40", respectively), after 72 h.
Development of a Novel Cell Encapsulation System 353
aggregation. This is relevant since previous studies showed that cell
aggregates could produce necrotic spaces within the capsules as a
consequence of poor mass transfer [18,40].
In previous studies, cells enclosed in liquefied beads improved growth
profile in comparison to the cells entrapped in solid capsules [18,26].
However, in this study, the solid and liquefied capsules, using sodium
alginate/iota-carrageenan as polyanions, showed a similar behavior.
These results can be explained by the mixture and proportion of
polymers, for example, iota-carrageenan is present in higher proportion
(70%) than sodium alginate (30%). The iota-carrageenan confers an
elastic structure to the core of the capsule, providing more flexibility as
opposed to the sodium alginate that has a rigid structure [37,41].
Cellular viability and proliferation were also determined by MTS tests
after culturing fibroblast cells 72 h in 30/70 SA-IC (solid and liquefied)
capsules. A sodium alginate/iota-carrageenan (30/70) mixture with cells
was also evaluated as a control. The cell viability decreased in the
encapsulated cells but increased in the cell/solution mixture (Figure 8).
However, the cell viability of both types of capsules did not show
significant differences after 72 h, indicating that the citrate treatment
may not be relevant to improve the permeability of the capsules and
hence for cell viability, using this polymeric formulation.
The cultured cell/solution did show increased cell viability with a
homogeneous growth, further demonstrating the non-cytotoxicity of this
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Figure 8.MTS tests of cell viability and proliferation of fibroblast entrapped within sodium
alginate/iota-carrageenan capsules and in the polymeric solution SA/IC (ratio: 30/70).
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mixture, confirming the MTT assays. These results also indicate that the
decrease in cell viability over time in the capsules may be due to a
decrease in permeability resulting from the membrane formation during
the capsule preparation. In fact, the cell growth is better in cells/solution
of SA-IC than in the capsules because the molecules and gases did not
have to cross the membrane present in the capsule to reach the cells.
Calcein-AM fluorescent staining was used to confirm the viability of
encapsulated cells (capsules 30/70, solid and liquefied); green and blue
staining was evident after 7 days of cell culture (Figure 9). These results
confirmed the permeability and non-toxicity of the capsule developed with
sodium alginate and iota-carrageenan polymers. No differences in cell
viability between encapsulated fibroblast in the solid and liquefied capsules
Figure 9. Fluorescent microscopic images of encapsulated fibroblasts stained with
Calcein-AM and DAPI dyes after: (A1–A3) 24h; (B1–B3) 48h; (C1–C3) 72 h; and (D1–D3)
7 days (5").
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were observed. The cells exhibited similar distribution and fluorescence
patterns in both types of capsules. However, after 7 days, the cells in both
capsules showed low fluorescence, possibly because of decreased cell
viability. The results obtained indicate that Calcein-AM and DAPI were
able to penetrate the alginate–carrageenan capsules containing living
fibroblast cells in suspension with intact membrane, reveal cell viability
within the construct. The capsules had differences in the cell viability and
proliferation, as confirmed in the MTS test. Furthermore, no cell
aggregates were detected by fluorescence staining (Figure 9).
CONCLUSIONS
Microcapsules developed via ionotropic gelation of sodium alginate and
iota-carrageenan solutions provided stable capsules when chitosan was
the main component of the capsule membrane. The mechanical proper-
ties of these capsules were influenced by the alginate/carrageenan ratio.
The short-term stability evaluations indicate that the capsules with
higher iota-carrageenan content are more stable and that the stability is
not affected by the citrate treatment. The cells encapsulated in both solid
and liquefied 30/70 SA-IC capsules maintained their viability and did not
aggregate. Citrate treatment did not improve the permeability of iota-
carrageenan/sodium alginate capsules made with high carrageenan (70%)
content. This new polymeric mixture of alginate with iota-carrageenan
produced a promising system for cell encapsulation that may have several
applications in tissue engineering and other cell therapies.
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